Celldex Therapeutics announced positive Phase 1 trial results for CDX-622, a novel bispecific antibody targeting soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP). The drug showed rapid, dose-dependent reductions in serum tryptase, indicating effective mast cell depletion, and was well-tolerated with no serious adverse effects. This dual-action approach may offer new treatment options for inflammatory and allergic diseases. Celldex plans further studies in asthma, allergic rhinitis, and food allergy to explore CDX-622's therapeutic potential.
In May, consumer prices for computer software and accessories surged 14.5% year-over-year, marking the largest increase since 2000. This spike is driven by AI data centers consuming most of the global chip supply, causing RAM prices to soar nearly 29...
XRP exchange-traded products attracted over $10 million in inflows for the fifth consecutive week, contrasting with Bitcoin and Ethereum funds which faced significant outflows. This continued demand for XRP ETFs highlights growing institutional inter...
British armed forces intercepted the Russian oil tanker SMYRTOS in the English Channel, marking the UK's first operation of its kind. The vessel was boarded by Royal Marine Commandos and law enforcement to disrupt Russia's efforts to evade sanctions ...
Ethereum is trading near $1,670 after experiencing one of its weakest nine-month periods, with a third consecutive quarter of double-digit losses. Despite a 66% drop from its late-2025 peak and bearish technical indicators, nearly 500,000 ETH were wi...
ETHGas's native token GWEI has surged from below $0.10 in June to over $0.20, marking a 750% rise since February lows and making it one of the top-performing altcoins despite a weak crypto market. The recent rally started from a key Fibonacci support...
